|Bid||3.6100 x 800|
|Ask||3.7000 x 800|
|Day's Range||3.6200 - 3.8400|
|52 Week Range||3.3500 - 7.8500|
|Beta (5Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.17|
La Jolla Pharmaceutical (LJPC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -37.31% and 2.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2021 and highlighted corporate progress.